A simple, rapid, and validated UPLC method was developed for the simultaneous quantitation of paracetamol (PAR), tizanidine (TIZ), aceclofenac (ACF), and nimesulide (NIM) either in pure forms or in their different tablet dosage forms. Chromatographic separation was attained on an ACQUITY UPLC ™ BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with a mobile phase consisting of 20 mM phosphate buffer (pH 7.0) : acetonitrile in the proportion (60 : 40 v/v) isocratically pumped at a flow rate of 1.25 mL·min −1 , and detection was monitored at 305 nm. All analytes were separated simultaneously at a retention time (t r ) of 1.42, 2.31, 3.63, and 5.62 min for PAR, TIZ, ACF, and NIM, respectively, with a total run time less than 6.0 min. e proposed method was validated according to ICH guidelines with respect to accuracy, precision, linearity, limit of detection, limit of quantitation, and robustness. Linearity was obtained over a concentration range of 81. 25-487.5, 0.5-3.5, 25-150, and 25-150 µg·mL 1 for PAR, TIZ, ACF, and NIM, respectively. e development method can be successfully employed in QC laboratories for the routine analysis of the investigated drugs in their new combination.
Introduction
Anybody during his lifetime would probably suffer from acute pain. Pain is considered a warning for a certain danger and in the same time as a reminder to protect injured limbs and tissues during the healing process [1] . Nowadays, combination therapy using nonsteroidal anti-inflammatory drugs (NSAIDs) is the favorable mainstay of pain relief due to its synergistic effects, multiple actions, quick relief, and patient acceptance [2] . Paracetamol (PAR) is a potent analgesic and antipyretic; chemically, it is N-(4-hydroxyphenyl)acetamide [3] . ere has been a trend over recent years for combining NSAIDs with paracetamol (PAR) for the management of acute postoperative pain, but the therapeutic superiority of the combination over either drug alone remains controversial [4, 5] . It was noted that PAR/NSAID combinations showed superior pain relief over PAR alone in 5 of 7 studies but over an NSAID alone in only 2 of 4 studies [6] . Nimesulide (NIM) is a derivative of p-nitrophenyl methanesulfonamide which belongs to selective COX-2 inhibitors, and it has a potent analgesic and antiinflammatory activity that could be used for the treatment of various inflammatory processes; chemically, it is N-(4-nitro-2-phenoxyphenyl)methanesulfonamide [7, 8] . Aceclofenac (ACF) is a phenylacetic acid derivative with anti-inflammatory and potent analgesic properties in the treatment of rheumatoid arthritis and osteoarthritis with an improved gastrointestinal tolerance; chemically, it is 2-[2-[2-(2,6-dichloroanilino)phenyl] acetyl]oxyacetic acid [9] . Tizanidine hydrochloride (TIZ) is a skeletal muscle relaxant that acts centrally in the treatment of spasticity due to multiple sclerosis and spinal cord injury; chemically, it is 5-chloro-N-(4,5-dihydro-1H-imidazole-2yl)-2,1,3-benzo-thiadiazol-4-amine hydrochloride [7] . e structure formulae of the investigated drugs are shown in Figure 1 . Various fixed-dose combinations of NSAIDs are available in the global market, and they vary in the amount of ingredients such as PAR, NIM (Nicip plus ® ) and/or ACF, TIZ (Zerodol MR ® ) combinations with faster onset and longer duration of analgesic and antipyretic effects than either drug alone [10, 11] .
e literature review reveals a number of reported methods for the determination of cited drugs either separately or in the presence of others such as UV-Vis spectrophotometry [12] [13] [14] , HPLC [12, [15] [16] [17] [18] , HPTLC [19] , CE [20] , LC-MS/MS [21] , and electrochemical method [22] . To the best of the author's knowledge, there is no single chromatographic method reported to cover the analysis of all mentioned drugs simultaneously in their tablets. e present work is aimed at developing a fully validated highly sensitive methodology according to ICH guidelines for the simultaneous determination of all the studied drugs in their pharmaceutical dosage forms using an isocratic chromatographic mode with an analysis time less than six minutes. e proposed method was successfully employed for routine quality control in the new marketed tablets. 
Experimental

Pharmaceutical Formulations.
e following dosage forms were analyzed: Nicip plus tablets from Cipla Pharmaceuticals (Maharashtra, India) claimed to contain 100 mg of nimesulide and 325 mg of paracetamol per tablet. Zerodol MR tablets from IPCA Laboratories Ltd. (Maharashtra, India) claimed to contain 100 mg of aceclofenac and 2 mg of tizanidine per tablet. Zerodol P ® tablets from IPCA Laboratories Ltd. (Maharashtra, India) were labeled to contain 100 mg of aceclofenac and 500 mg of paracetamol per tablet. Nobel MR ® tablets from Pharma Force Lab (Gondpur, India) were labeled to contain 100 mg of nimesulide, 325 mg of paracetamol, and 2 mg of tizanidine. ese tablets are commercially available in the Indian market and were purchased from public pharmacies in India with help of our colleagues.
Instrumentation
(i) All chromatographic analyses were performed using , and detection was monitored at 305 nm at room temperature. Filtration of the mobile phase was performed using a 0.45 μm Millipore membrane filter (Billerica, MA). e injection volumes were 2 μL. e peak areas were integrated automatically using Empower 2.0 software.
Standard Solutions.
Primary stock solutions of 1.0 mg·mL −1 PAR, TIZ, ACF, and NIM were prepared using the optimized mobile phase separately with the aid of ultrasonic bath. Freshly prepared working solutions were performed by dilution of the primary stock solutions with the same solvent to obtain a concentration of 4875, 35, 1500, and 1750 μg·mL −1 for PAR, TIZ, ACF, and NIM, respectively. In 10 mL volumetric flasks, the prepared working standard solutions of PAR, NIM, ACF, and TIZ were diluted in an appropriate volume with the mobile phase. All solutions were kept in the refrigerator (2-8°C) for one week without alteration. 
Procedures
Construction of Calibration Graphs.
Aliquot volumes of each working standard solution were accurately measured and transferred into a series of 10 mL volumetric flasks so that the final concentration was in the range of 81.25-487.5 µg·mL −1 for PAR, 0.5-3.5 µg·mL −1 for TIZ, 25-150 µg·mL −1 for ACF, and 25-150 µg·mL −1 for NIM. 2 μL was injected in triplicate and eluted with the mobile phase under the optimum chromatographic conditions. e calibration graphs were constructed by plotting the peak area versus the corresponding concentration, and the regression equation was computed.
Assay of PAR, TIZ, ACF, and NIM in LaboratoryPrepared
Mixtures. Synthetic mixtures were prepared through mixing different known amounts of working standard solutions with those of the other components in different ratios including those of commercial tablets to verify the precision of the proposed method for the analysis of such mixtures.
Assay of PAR, TIZ, ACF, and NIM in eir Tablets.
Ten tablets of each dosage form were weighed carefully and crushed completely to a fine powder. An accurately weighed amount equivalent to 325, 2, 100, and 500 mg of PAR, TIZ, ACF, and NIM, respectively, was transferred to a 100 mL volumetric flask and made up to 80.0 mL with methanol. All solutions were sonicated in water bath for 15 min, vortex mixed for 5 min, diluted to the mark with methanol, and finally filtered through a Millipore filter (0.45 µm pore size), and aliquots of all solutions were analyzed as appropriate (as discussed in Section 2.6.1).
e nominal contents of the tablets were calculated using the previously plotted calibration graph or the corresponding regression equation.
Validation.
System suitability tests were performed by injecting different concentrations of the working standard solutions for all drugs under investigation, and the separation factor was monitored throughout the validation process. Precision and intermediate precision (for three consecutive days) were checked using six replicate injections of all drugs, and peak areas were measured for which the relative standard deviation was computed. Limit of detection and limit of quantitation were determined at a signal-tonoise ratio for which LOD � 3.3 σ/S and LOQ � 10 σ/S, where σ is the standard deviation of the intercept and S is the slope derived from the calibration curve [23] . Linearity of the detector response was applied by preparing six calibration sample solutions starting with LOQ concentration. Each set of solutions was prepared in triplicates and analyzed for three successive days, and the % RSD and Y-intercept of the calibration curves were computed. e samples were stored in a tightly closed volumetric flask at 4°C temperature and analyzed after 48 hours.
Procedures for the Standard Addition Method (Checking Accuracy and Specificity).
Fixed portions of working dosage forms of solutions were quantitatively transferred to a 10.0 mL volumetric flask, and serial portions of working standard solutions of cited drugs were added to each flask. e solutions were mixed well and then completed with the used solvent to the volume, and chromatographic procedures were followed as mentioned in Section 2.6.1.
Results and Discussion
Method Development and Optimization of LC Conditions.
is is the first method that applies UPLC rather than HPLC for the determination of PAR, TIZ, ACF, and NIM simultaneously in one single run with many advantages as UPLC operates at much higher pressures, improved resolution, and fewer consumables. Different columns were tried including an ACQUITY UPLC BEH C18 ; injection volume 2.0 μL; and PDA detection at 305 nm.
Journal of Analytical Methods in Chemistrycolumn (100 mm × 2.1 mm, 1.7 μm), an ACQUITY UPLC BEH C8 column (100 mm × 2.1 mm, 1.7 μm), and a Zorbax SB-CN column (50 × 4.6 mm, 1.8 μm). e C8 and CN columns showed a bad resolution for PAR, tailing between ACF and TIZ, and long retention time for NIM as well. After several trials, the C18 column was the most suitable one with high resolution and produced symmetrical peaks and reasonable time of analysis less than 6 min. Preliminary trials with mobile phase compositions in different ratios between the organic modifier and aqueous phase at pH 2-7 were performed in an isocratic elution mode. e best peak shape was obtained by the use of 20 mM phosphate buffer and adjusted to pH 7.0 with dipotassium hydrogen phosphate and acetonitrile, in the proportion (60 : 40 v/v). Acetonitrile was selected as an organic constituent of the mobile phase to reduce the retention time, and the buffer was preferred to reduce the peak asymmetry and to achieve a good peak shape. Adjusting the flow rate at 1.25 mL·min −1 was crucial for the proposed method to enhance the resolution between the four peaks. Applying the flow rate more than that would increase the back pressure of the UPLC system more than 400 psi is not favorable. e optimum wavelength for detection was 305 nm at which much better detection response for all analytes was achieved. Under the described conditions, the analytes' peaks were well defined, resolved, and free from tailing at 1.42, 2.31, 3.63, and 5.62 for PAR, TIZ, ACF, and NIM, respectively, as shown in Figure 2 . To determine the linearity of HPLC detection response, calibration standard solutions of all drugs were prepared as described in the text. A linear correlation was obtained between the peak area versus the concentration of each drug.
e characteristic parameters for regression equations of the proposed UPLC method are given in Table 1 .
System Suitability.
e U.S. Pharmacopeia (USP) [24] states that system suitability tests are an integral part of liquid chromatographic methods.
ey are used to verify that the resolution and reproducibility of the chromatographic system are adequate for the analysis to be done. Parameters including resolution (R), peak symmetry, capacity factor (K′), and height equivalent theoretical plates (N) were calculated as shown in Table 2 . 
LOD and LOQ were also estimated. All results are summarized in Table 1 .
Accuracy and Precision.
e standard addition technique was performed to check the accuracy of the proposed method in which standard solutions of all cited drugs at different concentrations were added to the previously analyzed tablet samples. Furthermore, by applying the general analytical procedures, the total contents of all drugs were obtained. It was found that the obtained percentage recoveries were in the range of 97.6-102.33 as shown in Table 3 , while precision was checked by analyzing standard solutions at three different concentration levels. Intraday precision was performed at three different times within the same day, while interday assays were applied at three successive days.
e obtained results were expressed as percentage recovery, and relative standard deviations indicated the high accuracy and precision of the proposed UPLC method as shown in Table 4 .
Robustness.
It was studied to measure the reliability of the developed UPLC method by deliberate variations in the optimized parameters such as the change in temperature and pH of the buffer solution as illustrated in Table 5 .
Analysis of Laboratory-Prepared Mixtures.
e results obtained by application of the proposed method for some suggested laboratory-prepared binary mixtures are shown in Table 6 . As can be seen, the percentage recoveries in all cases were satisfactory, and the relative standard deviation value for both drugs did not exceed 2, indicating good accuracy and quality control applicability.
3.5. Specificity. It was studied by analyzing the synthetic mixtures for all studied drugs. e result showed good resolution and the absence of interference from other excipients as shown in Table 3 .
Conclusion
A highly sensitive and an accurate UPLC method was developed for the simultaneous determination of PAR, TIZ, ACF, and NIM either in pure forms or in their different tablet dosage forms. With respect to analysis time, the proposed method has a distinct advantage for run time less than 6 min when compared with other previously reported methods. e proposed method, by virtue of its high sensitivity, could be performed in QC laboratories suitable for the routine analysis.
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